Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid.
Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid.
复制标题
DOI：
10.4061/2010/986310
复制
发表时间：
2010-07-15
影响因子：
--
通讯作者：
Blennow, Kaj
中科院分区：
文献类型：
--
作者：
Bjerke, Maria;Portelius, Erik;Blennow, Kaj
背景。阿尔茨海默病（AD）患者的脑脊液（CSF）中42个氨基酸形式的β - 淀粉样蛋白（Aβ(42)）浓度降低。然而，不同中心所测Aβ(42)水平存在很大差异，这降低了该生物标志物作为诊断工具以及监测疾病修饰药物效果的实用性。对分析前和分析中的混杂因素就其对所测Aβ(42)水平的影响进行了研究。方法。在测量Aβ(42)之前对脑脊液样本的等份试样进行不同处理，或者使用不同的市售xMAP或酶联免疫吸附测定（ELISA）方法进行分析。结果。影响脑脊液Aβ(42)水平的混杂因素包括在不同类型的试管中储存、用含洗涤剂的缓冲液稀释、血浆污染、热处理以及用于定量的免疫测定方法的来源。结论。为了开展多中心研究，有必要制定一个标准化的方案以尽量减少分析前和分析中的混杂因素。
Background. Patients afflicted with Alzheimer's disease (AD) exhibit a decrease in the cerebrospinal fluid (CSF) concentration of the 42 amino acid form of beta-amyloid (Abeta(42)). However, a high discrepancy between different centers in measured Abeta(42) levels reduces the utility of this biomarker as a diagnostic tool and in monitoring the effect of disease modifying drugs. Preanalytical and analytical confounding factors were examined with respect to their effect on the measured Abeta(42) level. Methods. Aliquots of CSF samples were either treated differently prior to Abeta(42) measurement or analyzed using different commercially available xMAP or ELISA assays. Results. Confounding factors affecting CSF Abeta(42) levels were storage in different types of test tubes, dilution with detergent-containing buffer, plasma contamination, heat treatment, and the origin of the immunoassays used for quantification. Conclusion. In order to conduct multicenter studies, a standardized protocol to minimize preanalytical and analytical confounding factors is warranted.